In an exploratory analysis of the CANTOS trial, canakinumab reduced cardiovascular events in TET2 CHIP carriers (HR 0.38); the interaction was not significant.
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).